
RCEL Stock Forecast & Price Target
RCEL Analyst Ratings
Bulls say
AVITA Medical reported a full-year revenue of approximately $71.6 million for 2025, which marks an 11% increase from $64.3 million in 2024 and aligns with the company's revised guidance. The company experienced an improvement in net cash use, decreasing from about $6.2 million in the third quarter to approximately $5.1 million, indicating enhanced financial efficiency. Additionally, management’s revenue guidance for 2026, projected between $80 million and $85 million, reflects anticipated commercial momentum driven by deeper market penetration and the integration of its product portfolio.
Bears say
AVITA Medical's revenue expectations have been lowered, leading to a significant reduction in target valuation from $14.0 to $10.0. The company reported a net loss of $11.6 million, equating to $0.38 per share, which remains unchanged compared to the prior year period when the loss was $11.6 million or $0.44 per share. Additionally, despite its innovative RECELL system being utilized in US burn centers, the limited marketing efforts abroad and reliance on a single product could pose challenges for future growth.
This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
RCEL Analyst Forecast & Price Prediction
Start investing in RCEL
Order type
Buy in
Order amount
Est. shares
0 shares